Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221828 · ClinicalTrials.gov registry record · Phase 2
Trial of NanoPac Focal Therapy for Prostate Cancer
A Phase 2 study, sponsored by NanOlogy.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04221828: Clinical Trial Phase 2 study, sponsored by NanOlogy.
NCT04221828 is a Phase 2 study that was terminated before completion, run by NanOlogy. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04221828, a Phase 2 study, was terminated before completion, sponsored by NanOlogy.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
Primary Outcome
Treatment emergent adverse events (including changes in laboratory assessments, physical examination findings, and vital signs)
Interventions
- DRUG NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2021-02-08 |
| Phase | Phase 2 |
Why NCT04221828 stopped before completion
NCT04221828 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension is the first listed.
NCT04221828 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04221828 about?
NCT04221828 is a clinical study titled "Trial of NanoPac Focal Therapy for Prostate Cancer". This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
What is the current status of trial NCT04221828?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2020-10-20. Estimated completion is 2021-02-08.
What interventions are being tested in trial NCT04221828?
The interventions under investigation include: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension (DRUG).
Who is sponsoring clinical trial NCT04221828?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04221828's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI